AMPH — AMPHASTAR P (Healthcare >> Drug Manufacturers - Specialty & Generic)
AMPH FAQ
What is AMPH's P/E ratio?
AMPHASTAR P (AMPH) currently trades at a P/E ratio of 11.04.
What is AMPH's ROE?
AMPHASTAR P reports a Return on Equity (ROE) of 10.24%.
What is AMPH's dividend yield?
AMPHASTAR P offers a dividend yield of 0.00%.
What is AMPH's Deepscope Quality Score?
Deepscope rates AMPH's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy AMPH?
Deepscope's AI Timing Score for AMPH is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does AMPH belong to?
AMPHASTAR P is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange.
|
USD 19.74
Price
1.04
(5.56%)
Day Change
|
|
|---|
AMPH, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is ok , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
706
|
| Magic Formula Rank by ROE |
706
|
| Magic Formula Rank by ROIC |
775
|
| Price | 19.74 |
| PBV / Sector |
1.13 / 2.76
GREAT
|
| Earning Per Share | 1.79 |
| PE / Sector |
11.04 / 23.64
GOOD
|
| PEG or PE/Growth / Sector |
0.99 / 0.13
|
| Average 1M Daily Value |
15.84 M
GREAT
|
| Average 1W Daily Value |
11.61 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
60% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:26 |
| Symbol | AMPH |
| Name | AMPHASTAR P |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 44.09 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 875.02 / 9,835.56 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 11570 6th Street, Rancho Cucamonga, CA, United States, 91730
Phone: 909 980 9484
Website: https://www.amphastar.com
Employees: 1,976
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
Google